MRMD · Marimed Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 13, 2026TL;DR. MariMed posted a record quarterly revenue of $41.9 million, up roughly 6% sequentially and year-over-year, with adjusted EBITDA of $3.9 million (+10% sequentially) but margin pressure persists as non-GAAP gross margin fell to 40% from 41.8% a year ago amid price compression; the Columbus, Ohio dispensary remains on track to contribute later this year, a New York launch is planned for the first half of 2027, and management noted an upcoming DEA inspection tied to medical cannabis rescheduling.
- + Record quarterly revenue of $41.9 million, up ~6% sequentially and year-over-year
- + Wholesale revenue grew ~8% year-over-year and 6% sequentially with branded share gains
- + Retail revenue grew 7% sequentially, with transactions up 7% and Thrive Perks membership up 14% YTD
- + Adjusted EBITDA grew ~10% sequentially to $3.9 million; cash from operations remained positive
- + On schedule for new Ohio Columbus dispensary to contribute later this year and New York launch in 1H27
- − Non-GAAP gross margin compressed ~180 bps year-over-year to 40% on price competition
- − Adjusted EBITDA margin fell to 9.4% from 12.1% a year ago
- − Wholesale-partner bankruptcy drove a Q2 bad-debt/operating-expense write-off
- − Massachusetts retail under pressure from market saturation
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Non-GAAP Adjusted EBITDA non-GAAP | $7.5M | Six months ended June 30 | — |
| Non-GAAP Adjusted EBITDA margin non-GAAP | 9% | Six months ended June 30 | — |
| Non-GAAP Gross margin non-GAAP | 40% | Six months ended June 30 | — |
| Non-GAAP net (loss) income non-GAAP | -5.53M | Six months ended June 30, 2026 | — |
| Non-GAAP Operating expenses non-GAAP | 29.55M | Six months ended June 30, 2026 | — |
| Thrive Perks Loyalty Program membership | 14% | Q2 FY2026 (since the beginning of the year) | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MRMD
this stock
Marimed Inc.
|
$22.97M | -39.4% | +11.6% | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$62.65B | +28.8% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$48.88B | +1.1% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$48.14B | +30.9% | +4.3% | 67.7 | 2.6% |
|
HLN
Haleon plc
|
$44.72B | +0.6% | — | — | 0.6% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 0.2%
- Net QoQ
- -4.3K sh
- Top holder
- Canton Hathaway, LLC
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MRMD | -9.1% | -19.7% | -35.2% | -18.6% | -39.4% |
| SPY | -1.5% | -0.9% | +7.7% | +0.5% | +12.4% |
| vs SPY | -7.6% | -18.8% | -42.9% | -19.1% | -51.8% |